LongView Wealth Management Has $2.17 Million Position in Johnson & Johnson (NYSE:JNJ)

LongView Wealth Management boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,831 shares of the company’s stock after acquiring an additional 123 shares during the quarter. LongView Wealth Management’s holdings in Johnson & Johnson were worth $2,168,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Cidel Asset Management Inc. raised its position in Johnson & Johnson by 4.1% during the second quarter. Cidel Asset Management Inc. now owns 16,429 shares of the company’s stock valued at $2,401,000 after acquiring an additional 650 shares in the last quarter. Pallas Capital Advisors LLC raised its position in shares of Johnson & Johnson by 4.6% in the second quarter. Pallas Capital Advisors LLC now owns 76,826 shares of the company’s stock valued at $11,940,000 after purchasing an additional 3,401 shares during the period. MBE Wealth Management LLC raised its position in shares of Johnson & Johnson by 13.4% in the second quarter. MBE Wealth Management LLC now owns 2,264 shares of the company’s stock valued at $331,000 after purchasing an additional 268 shares during the period. Ninety One UK Ltd raised its position in shares of Johnson & Johnson by 59.0% in the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the company’s stock valued at $980,579,000 after purchasing an additional 2,489,925 shares during the period. Finally, ZWJ Investment Counsel Inc. raised its position in shares of Johnson & Johnson by 3.8% in the second quarter. ZWJ Investment Counsel Inc. now owns 208,822 shares of the company’s stock valued at $30,521,000 after purchasing an additional 7,685 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.67 on Wednesday, hitting $160.83. The stock had a trading volume of 892,734 shares, compared to its average volume of 7,282,667. The firm’s 50 day moving average price is $152.89 and its 200-day moving average price is $153.09. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $167.84. The company has a market capitalization of $387.07 billion, a price-to-earnings ratio of 10.00, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the previous year, the business posted $2.80 earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. The Goldman Sachs Group dropped their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, August 5th. TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.